
|Articles|October 1, 2003
Melanoma Activist
Chicago - An orally active small molecule inhibitor of Raf kinase, the first of its class to enter clinical trials, is well tolerated when combined with standard chemotherapy agents, and may have activity against metastatic melanoma, Keith T. Flaherty, M.D., said at the annual meeting of the American Society of Clinical Oncology.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
4
Moving Past Dermal Filler Trends to Focus on Healthy Skin Aging
5














